Modules
Modules
Genomics Primer
Genomics Primer
Overview/Key Objectives
What are Eukaryotic Cells?
DNA Definition
What are Chromosomes?
What is a Genome?
Regulation of Gene Expression in Eukaryotes
Genetic Alterations
References
Assessment Questions
Course Introduction
Course Introduction
Overview/Key Objectives
What is Precision Medicine?
Precision Medicine in the Clinic
Direct-to-Consumer Genomic Testing
Ongoing Genomic Research and Big Data in Precision Medicine
References
Assessment Questions
Pathology Assessment of Tumor Tissue
Pathology Assessment of Tumor Tissue
Overview/Key Objectives
Introduction to the Pathology Laboratory
Specimen Preparation
Initial Pathology Assessment
Common Pathology Tests Performed in Oncology
References
Assessment Questions
Introduction to Liquid Biopsies
Introduction to Liquid Biopsies
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
Lung Cancer: Assessment, Treatment
Lung Cancer: Assessment, Treatment
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK Anaplastic Lymphoma Kinase
ROS1 ROS Proto oncogene 1
BRAF v raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
NTRK3 Fusion
NTRK3 Fusion
Initial Diagnosis
Clinical Progress and Treatment
Imaging
Pathology Part 1
Pathology Part 2
Discussion and Proposed Potential Therapies
References
Whole-Genome Sequencing
Whole-Genome Sequencing
Overview/Key Objectives
What is Whole-Genome Sequencing?
Sanger Sequencing
Whole-Genome Sequencing Methods
Whole-Genome vs. Whole-Exome Sequencing vs. Targeted Sequencing Panels
Strengths and Limitations of Next-Generation Sequencing
Next-Generation Sequencing in the Research and Clinic Settings
Importance of Bioinformatics
References
Assessment Questions
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Overview/Key Objectives
Clinical Settings for Genomic Testing
Considerations When Choosing a Genomic Testing Approach
Liquid Biopsies
Frequently Discussed Topics
Future of Genomic Medicine
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Visit Healio.com
Modules
Genomics Primer
Overview/Key Objectives
What are Eukaryotic Cells?
DNA Definition
What are Chromosomes?
What is a Genome?
Regulation of Gene Expression in Eukaryotes
Genetic Alterations
References
Assessment Questions
Course Introduction
Overview/Key Objectives
What is Precision Medicine?
Precision Medicine in the Clinic
Direct-to-Consumer Genomic Testing
Ongoing Genomic Research and Big Data in Precision Medicine
References
Assessment Questions
Pathology Assessment of Tumor Tissue
Overview/Key Objectives
Introduction to the Pathology Laboratory
Specimen Preparation
Initial Pathology Assessment
Common Pathology Tests Performed in Oncology
References
Assessment Questions
Introduction to Liquid Biopsies
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
Lung Cancer: Assessment, Treatment
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK Anaplastic Lymphoma Kinase
ROS1 ROS Proto oncogene 1
BRAF v raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
Whole-Genome Sequencing
Overview/Key Objectives
What is Whole-Genome Sequencing?
Sanger Sequencing
Whole-Genome Sequencing Methods
Whole-Genome vs. Whole-Exome Sequencing vs. Targeted Sequencing Panels
Strengths and Limitations of Next-Generation Sequencing
Next-Generation Sequencing in the Research and Clinic Settings
Importance of Bioinformatics
References
Assessment Questions
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Overview/Key Objectives
Clinical Settings for Genomic Testing
Considerations When Choosing a Genomic Testing Approach
Liquid Biopsies
Frequently Discussed Topics
Future of Genomic Medicine
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Login
Register
My Account
My Curriculum
Log Out
Visit Healio.com
Toggle navigation
Healio
Hematology/Oncology
Learn Genomics
Genomics Primer
Lung Cancer: Assessment, Treatment
Module Content
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR: Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK: Anaplastic Lymphoma Kinase
ROS1: ROS Proto-oncogene 1
BRAF: v-raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR: Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK: Anaplastic Lymphoma Kinase
ROS1: ROS Proto-oncogene 1
BRAF: v-raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
0%
Your Module Progress
References
Karachaliou N, Fernandez-Bruno M, Paulina Bracht JW, et al: EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients.
Translational Cancer Research
:S23-S47, 2018
Blackhall F, Barlesi F, Hochmair M, et al: Oncogenic Drivers in Advanced NSCLC: Navigating an Evolving Landscape to Optimise Patient Outcomes, European Society for Medical Oncology (ESMO). Virtual Congress,
EMJ Oncol
, 2020, pp 33-42
Loh Z, Mitchell P, John T, et al: RET-rearranged non-small-cell lung cancer and therapeutic implications.
Intern Med
J 49:1541-1545, 2019
Marmarelis ME, Langer CJ: Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
Clin Lung Cancer
21:395-406, 2020
Guo Y, Cao R, Zhang X, et al: Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.
Onco Targets Ther
12:10343-10360, 2019
Du X, Shao Y, Qin HF, et al: ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 9:423-430, 2018
Yu HA, Planchard D, Lovly CM: Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
Am Soc Clin Oncol Educ Book
38:726-739, 2018
Roviello G, D'Angelo A, Sirico M, et al: Advances in anti-BRAF therapies for lung cancer.
Invest New Drugs
39:879-890, 2021
Ou SI, Zhu VW, Nagasaka M: Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020.
JTO Clin Res Rep
1:100015, 2020
Adderley H, Blackhall FH, Lindsay CR: KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
EBioMedicine
41:711-716, 2019
Salgia R, Pharaon R, Mambetsariev I, et al: The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Cell Rep Med
2:100186, 2021
Zhao J, Xia Y: Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review.411-425, 2020
Harada G, Santini FC, Wilhelm C, et al: NTRK fusions in lung cancer: From biology to therapy.
Lung Cancer
161:108-113, 2021
Recondo G, Bahcall M, Spurr LF, et al: Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Clin Cancer Res
26:2615-2625, 2020
Drusbosky LM, Rodriguez E, Dawar R, et al: Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
J Hematol Oncol
14:50, 2021
Riudavets M, Sullivan I, Abdayem P, et al: Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
ESMO Open
6:100260, 2021
Reck M, Carbone DP, Garassino M, et al: Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Ann Oncol
32:1101-1110, 2021
Vyse S, Huang PH: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Signal Transduct Target Ther
4:5, 2019
Xu H, Yang G, Li W, et al: EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.
Front Oncol
11:713483, 2021
Miles B, Mackey JD: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook.
Cureus
13:e13470, 2021
US Food and Drug Administration: FDA approves dacomitinib for metastatic non-small cell lung cancer, (ed 12/14/2018). US Food and Drug Administration, FDA, 2018
US Food and Drug Administration: FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations, in Administration UFaD (ed): (ed 04/19/2018), US Food and Drug Administration, 2018
Lindeman NI, Cagle PT, Aisner DL, et al: Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Arch Pathol Lab Med
142:321-346, 2018
Chan BA, Hughes BG: Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Transl Lung Cancer Res
4:36-54, 2015
Harrison PT, Vyse S, Huang PH: Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Semin Cancer Biol
61:167-179, 2020
Lin JJ, Shaw AT: Recent Advances in Targeting ROS1 in Lung Cancer.
J Thorac Oncol
12:1611-1625, 2017
Russo A, Lopes AR, Scilla K, et al: NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC).
Precis Cancer Med
3, 2020
Thank you for participating in this module. Click below to download the certificate.
Download Certificate of Participation
Previous Section
Return to Home
×
Close
Notice